Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer

American Journal of Clinical Pathology

Volumn 139, Issue 6, 2013, Pages 746-753

  Koh, Young Wha ^a   Lee, Hee Jin ^a   Ahn, Jin Hee ^a   Lee, Jong Won ^a   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Lewis X; Prognosis; Triple negative breast cancer

Indexed keywords

SIALYL LEWIS X ANTIGEN;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

LEWIS X; PROGNOSIS; TRIPLE-NEGATIVE BREAST CANCER;

ANTIGENS, CD15; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84878385042     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP2E6QNDIDPTTC     Document Type: Article

References (42)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-1948.
2. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer: current status and future directions. Ann Oncol. 2009;20:1913-1927.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434. (Pubitemid 47219710)
4. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
5. Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13:R22.
6. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol. 1996;179:358-369. (Pubitemid 26276103)
7. Masmiquel L, Castro-Forns M, de Torres I, et al. Leu-M1 immunoreactivity and phaeochromocytoma. J Clin Pathol. 1997;50:168-170. (Pubitemid 27093038)
8. Neuhold N, Langle F, Gnant M, et al. Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma. J Cancer Res Clin Oncol. 1992;118:629-634.
9. Schroder S, Schwarz W, Rehpenning W, et al. Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland. J Cancer Res Clin Oncol. 1988;114:291-296.
10. Schroder S, Schwarz W, Rehpenning W, et al. Prognostic significance of Leu-M1 immunostaining in papillary carcinomas of the thyroid gland. Virchows Arch A Pathol Anat Histopathol. 1987;411:435-439. (Pubitemid 17142075)
11. Kadota A, Masutani M, Takei M, et al. Evaluation of expression of CD15 and sCD15 in non-small cell lung cancer. Int J Oncol. 1999;15:1081-1089.
12. Shirahama T, Ikoma M, Muramatsu T, et al. Expression of SSEA-1 carbohydrate antigen correlates with stage, grade and metastatic potential of transitional cell carcinoma of the bladder. J Urol. 1992;148:1319-1322.
13. Konety BR, Ballou B, Jaffe R, et al. Expression of SSEA-1 (Lewis(x)) on transitional cell carcinoma of the bladder. Urol Int. 1997;58:69-74. (Pubitemid 27107517)
14. Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 2009;15:135-147.
15. Calvo F, Martin PM, Jabrane N, et al. Human breast cancer cells share antigens with the myeloid monocyte lineage. Br J Cancer. 1987;56:15-19. (Pubitemid 17097691)
16. Siwek B, Larsimont D, Lacroix M, et al. Establishment and characterization of three new breast-cancer cell lines. Int J Cancer. 1998;76:677-683. (Pubitemid 28243940)
17. Narita T, Funahashi H, Satoh Y, et al. Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer. 1993;71:3044-3053. (Pubitemid 23145537)
18. Mordoh J, Silva C, Albarellos M, et al. Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J Immunother Emphasis Tumor Immunol. 1995;17:151-160.
19. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987. (Pubitemid 29318825)
20. Nakagoe T, Fukushima K, Itoyanagi N, et al. Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol. 2002;128:257-264. (Pubitemid 34591583)
21. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376. (Pubitemid 351413917)
22. Elola MT, Capurro MI, Barrio MM, et al. Lewis x antigen mediates adhesion of human breast carcinoma cells to activated endothelium: possible involvement of the endothelial scavenger receptor C-type lectin. Breast Cancer Res Treat. 2007;101:161-174. (Pubitemid 46115422)
23. Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer. 2004;4:82.
24. Zabicki K, Colbert JA, Dominguez FJ, et al. Breast cancer diagnosis in women < or = 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time. Ann Surg Oncol. 2006;13:1072-1077. (Pubitemid 44337966)
25. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (< 35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13:273-279. (Pubitemid 34704980)
26. Fredholm H, Eaker S, Frisell J, et al. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4:e7695.
27. Konigsberg R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients. Eur J Cancer. 2012;48:2962-2988.
28. Monhollen L, Morrison C, Ademuyiwa FO, et al. Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. Histopathology. 2012;61:365-377.
29. Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2012;13:31-39.
30. Shi ZR, McIntyre LJ, Knowles BB, et al. Expression of a carbohydrate differentiation antigen, stage-specific embryonic antigen 1, in human colonic adenocarcinoma. Cancer Res. 1984;44:1142-1147. (Pubitemid 14151518)
31. Itzkowitz SH, Shi ZR, Kim YS. Heterogeneous expression of two oncodevelopmental antigens, CEA and SSEA-1, in colorectal cancer. Histochem J. 1986;18:155-163.
32. Son MJ, Woolard K, Nam DH, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4:440-452.
33. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2010;15(suppl 5):39-48.
34. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718-730.
35. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
36. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
37. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660-4671. (Pubitemid 41032603)
38. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116-4124.
39. Farmer P, Bonnefoi H, Anderle P, et al. A stromarelated gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15:68-74.
40. Whitney AR, Diehn M, Popper SJ, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A. 2003;100:1896-1901. (Pubitemid 36254545)
41. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158-5165.
42. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735-6741.